EN 简
search
EN 简

Pipeline

Our Hematology and Autoimmune Pipeline: Expanding Indications to Benefit Patients Hematologic Malignancies and Autoimmune Diseases

<p>Our Hematology and Autoimmune Pipeline: Expanding Indications to Benefit Patients Hematologic Malignancies and Autoimmune Diseases</p>

Information as of: March 2025

Abbreviations: LBCL = large B-cell lymphoma; FL = follicular lymphoma; MCL = mantle cell lymphoma; ALL = acute lymphoblastic leukemia; CLL = chronic lymphocytic leukemia; MM = multiple myeloma; NHL = non-Hodgkin lymphoma; SLE = systemic lupus erythematosus.

* Mainland China, Hong Kong, Macau refer to Mainland China, Hong Kong (China), Macau (China), respectively.

1.Relma-cel is based on the same chimeric antigen receptor (“CAR”) construct as the product lisocabtagene maraleucel (Breyanzi or lisocabtagene or liso-cel) of Juno, which was approved by the U.S. Food and Drug Administration (“FDA”) in February 2021.

2.JWCAR129 is based on the same CAR construct as Juno’s product orvacabtagene autoleucel (orvacel).

3.SLE is a chronic autoimmune disease characterized by the production of autoantibodies and abnormal B-lymphocyte function.

Our Pipeline Beyond Heme: Expanding Solid Tumor Indications High Incidence Diseases in China: HCC, Lung Cancer and More

<p>Our Pipeline Beyond Heme: Expanding Solid Tumor Indications High Incidence Diseases in China: HCC, Lung Cancer and More</p>

Information as of: March 2025

Abbreviations: HCC = hepatocellular carcinoma; NSCLC = non-small cell lung cancer; AFP = alpha-fetoprotein; GPC3 = glypican-3; r/r = relapsed or refractory; 3L = third-line; 2L = second-line; HAS= hepatoid adenocarcinoma of the stomach；MAGE A4= melanoma associated antigen A4; DLL3= Delta-like ligand 3;

* Mainland China, Hong Kong, Macau and Taiwan refer to Mainland China, Hong Kong (China), Macau (China) and Taiwan (China), respectively.

1.JWATM204 is in a Phase I investigator-initiated trial in China. Eureka’s products based on the CAR constructs underlying JWATM203 and JWATM204 are currently in Phase I/II trials in the US conducted by Eureka under an IND application. In November 2021, the FDA granted Fast Track

Designation to Eureka’s counterpart to JWATM203 for the treatment of hepatoblastoma (“HB”) and HCC in pediatric patients, as well as “rare pediatric disease designation” for the treatment of HB. In February 2022, the FDA granted Orphan Drug Designation to Eureka’s counterparts to JWATM203 and JWATM204.

2.Developing using Lyell technology.